Product Compliance And Certification For Medical Device In Mexico

Decide what the product is before assigning a class

Article 262 of the General Health Law covers medical equipment, prostheses and orthoses, diagnostic agents (including in-vitro diagnostics), dental supplies, surgical and wound-care materials and certain hygiene products. Medical purpose and claims matter. Record whether the product is sterile, invasive, implantable, active, software-based, reusable or supplied as a system/accessory. Mexico uses risk Classes I, II and III, but no example alone establishes a class; check the applicable FEUM medical-device supplement rules and the exact product description.

Do not confuse three decisions: (1) is it a medical device, (2) is it specifically on an Annex of the 7 July 2025 agreement, and (3) if registration is required, which class and application route applies? “Low risk” does not automatically mean “no registration”; a sterile version can invalidate a low-risk assumption under the agreement’s notes.

Mexico medical-device route matrix: five different outcomes

The 2025 agreement replaced the old 2011/2014 listings. Search the actual Annex wording, not a remembered “exemption list”; capture a screenshot or legal extract, model numbers and the rationale. The three Annex outcomes are mutually different legal conclusions, not interchangeable shortcuts.

Concrete check: Annex I item 10 names a non-sterile foam, hydrogel or nylon absorbent dressing for external wounds and still requires registration; Annex II item 93 lists manual or motorized wheelchairs without sanitary registration for the matching scope. These are examples of the published wording, not blanket classifications for related models or additional claims.

Pre-2025 exemption letters: a separate transition—not a new exemption

The 7 July 2025 agreement revoked the 2011 and 2014 list agreements, but contains special transitional rules for existing official exemption letters covering products now in Annex I. A manufacturer entering Mexico for the first time cannot assume that these legacy rights apply.

Keep the original exemption letter, product description, Annex number, filing evidence and COFEPRIS correspondence in the launch file. The Annex notes also state that sterile devices are not treated as low-risk; never extend an exemption to a sterile variant or a differently claimed product without reassessment.

Numbering caution: the published Annex I list ends at item 93, although the agreement’s second transitional clause refers to items 76–116. Do not infer that items 94–116 exist or qualify. Match the actual published entry and obtain clarification from COFEPRIS if this inconsistency affects a legacy letter.

Evidence that changes with the actual device

For COFEPRIS-04-060 the August 2025 administrative simplification agreement identifies the application form, fee proof, proposed Spanish label, scientific/technical safety–efficacy–quality information and Spanish instructions/manual when applicable. For foreign manufacture it additionally identifies a free-sale certificate or equivalent, GMP evidence or accepted equivalent, and a manufacturer representation letter in the specified circumstances. COFEPRIS-04-070 has a different, reduced list. This is a dossier map, not a guarantee that every test above is mandatory for every device.

Spanish labeling: current rule and the 2027 changeover

As of 14 October 2026, NOM-137-SSA1-2008 remains the operative medical-device labeling standard: review Spanish product identification, responsible entities, relevant instructions, warnings, traceability and actual approved claims. NOM-137-SSA1-2025 was published on 19 May 2026 but is scheduled to enter into force on 14 May 2027, when it replaces the 2008 standard. Its transition clause gives a limited 180-day period for specified packaging materials/finished stocks whose information cannot be changed; it is not a general postponement of compliance. Create a label-version migration plan now and reconfirm the rule immediately before release.

Importation, local responsibilities and release gates

Treat sanitary registration, factory compliance, customs import authorization and distribution as separate gates. A foreign FDA/CE authorization does not itself grant Mexican market access: COFEPRIS has a reliance/abbreviated path, but eligibility and document equivalence must be checked against its current guidance. NOM-241-SSA1-2025 addresses manufacturing practices; NOM-240-SSA1-2012 addresses technovigilance. Their obligations can remain relevant even to Annex II devices.

• Classification gate: signed intended-use statement, Annex comparison, risk class and rationale approved for each model.
• Applicant/site gate: identify Mexican applicant/holder, manufacturer, importer, distributor, relevant operating notice and sanitary-responsible arrangements; validate who legally holds each obligation.
• Product gate: registration number or documented legal basis for no registration, scope of models, factory evidence and approved Spanish label/IFU.
• Border gate: match customs goods description to regulatory scope; check COFEPRIS-01-014 for registered imports or another applicable permit. For an actual Annex II match, follow its special no-permit declaration rule.
• After-sale gate: retain lot/serial traceability, complaint handling, adverse-incident escalation, corrective action and distributor information.

NOM-241-SSA1-2025 has been in force since 30 November 2025; unlike an optional ISO certificate, it is a Mexican official standard. Verify the specific manufacturing and establishment obligations against the actual activity and regulatory status.

Control changes after the first shipment

Before changing intended use, claims, sterile state, component formulation, manufacturing site, software version, accessories, or the commercial entity holding the registration, compare the proposed version with the approved registration and applicable modification criteria. Classify the change as administrative/technical and determine whether COFEPRIS filing or a new assessment is required before shipping the changed SKU. The same check applies if an Annex-listed description stops matching the revised product.

Five-step classification and launch file

1. Freeze the Spanish and original-language intended-use statements, all models, components, photographs and promotional claims.
2. Create an Annex I/II/III comparison with the 7 July 2025 agreement; identify why the exact SKU does or does not fit.
3. If registration remains necessary, document the Mexican class, technical-file gaps and standard versus reliance eligibility; check COFEPRIS’s 2026 registration guidance.
4. Name each Mexican actor and the lawful import route; reconcile documents, invoice descriptions, labels and customs classification.
5. Approve a dated launch decision recording unresolved questions and the exact event requiring re-review (new claim, change, new NOM, authority update).

A device worn on the body may introduce sensor, radio and software-specific considerations: use the dedicated wearable medical-device assessment for Mexico for that narrower product. This page owns the cross-regime decision for medical devices generally, including IVDs, sterile goods, equipment and accessories.

Official primary sources

Use the original Spanish legal texts for final classification; COFEPRIS guides are operational guidance, not legislation.

• General Health Law, art. 262
• 2025 Annex I/II/III low-risk agreement
• 2025 application simplification (04-060/04-070)
• NOM-241-SSA1-2025 manufacturing practices
• NOM-137-SSA1-2008 current labeling
• NOM-137-SSA1-2025 future labeling
• Official 2027 entry-into-force record
• NOM-240-SSA1-2012 technovigilance
• COFEPRIS current register and guidance
• COFEPRIS reliance pathway
• COFEPRIS import permits

Product-specific questions